Compliant. Efficient. Commercial.
How Does Your Companies Manufacturing Strategy Compare?
"The Global Cell And Gene Therapy Market Is Estimated To Be Worth More Than £35Billion By 2026” – Are Your Processes Market Ready?
With the past year seeing Kite Therapeutics and Novartis make headlines for their groundbreaking therapeutic approvals, and a host of innovative biotech companies quickly advancing their production towards commercialisation, the Cell and Gene industry is rapidly transforming the standard of care for rare diseases and critical conditions.
While there is a huge opportunity for industry growth, ever present challenges surrounding raw material selection and qualification, regulatory compliance, systems scalability and closed system processing prove barriers to achieving efficient commercial manufacturing scale.
Given the number of critical process challenges, the annual Cell and Gene Therapy Manufacturing Forum is the industries dedicated forum to address their process development, technical adoption and manufacturing challenges. With presentations on improving cost efficiency, innovative strategies for commercialisation, achieving optimised manufacturing scalability and maintaining GMP compliance, this year’s iteration is one not to be missed!
Focused Solely On Optimising Your Cell and Gene Manufacturing Process and Networks
- Based on 25+ in-depth industry research calls, this year’s agenda is designed to address your biggest ATMP based production challenges in one leading manufacturing specific platform
- Join a curated program taking you from translation and collaboration to ensuring GMP compliance and optimising scalability– this year’s forum is your one stop shop for building manufacturing capabilities that are compliant, efficient and commercial
- Get involved in the industries most interactive conference that ensures you can leverage the insights and expertise of every session to leave with answers and strategies for all of your biggest manufacturing and process development challenges
Optimise Every Facet Of Your Manufacturing Strategy
- With sessions on industry collaboration, academic translation, raw materials selection and qualification and achieving scalable manufacturing processes for allogenic and autologous therapies, your hands on, daily challenges are addressed through a series of the industries leading case studies and interactive thought exchanges
- Gain a holistic industry perspective from the academic environment through to big pharma companies, with case studies shared from Novartis, Novo Nordisk, GammaDelta Therapeutics, Celyad and UCL among others
- Engage in our GMP compliance training day to ensure that your process development optimisation does not come at the cost of process compliance.
Building Awareness, Opportunity and Tangible Takeaways
- This event is tightly focused on networking, industry analysis, technology adoption and learning opportunities for the cell and gene industries leading experts
- All attendees participate actively across the full forum, with case studies, think tanks, brainstorming sessions, tech demonstrations and panel discussions – generating unparalleled industry engagement and product development opportunities
- Join the industry's only manufacturing focused forum and engage in a conversation unlike any other. Where industry updates and daily challenges meet industry brainstorming and solution adoption
Meet Our Speakers:
VP, Cell Therapy Manufacturing
Chief Technical Officer
Director Cell and Gene Therapy QA
Senior Manager, QA, GBS QA Quality Governance Risk and Compliance, Global Records Manager
Head, Process Development
Associate Director CMC
Group Lead, Process Development and Manufacturing
RheinCell Therapeutics GmbH
Development Scientist - Stem Cell Process Development
Senior Manager, Process Development
Head of Production and Process Innovation
Head of Translational Research Group
Chief Technology and Manufacturing Officer
Senior GMDP Inspector - Inspection, Enforcement and Standards
Product Steward, Cell and Gene Therapy Unit - Kymriah, C&G Technical Operations
CTO and Head of Manufacturing
Centre for Cell Manufacture Ireland (CCMI)
Head of Advanced Therapies
NIBSC - A Division of MHRA
Process Development Engineer
Vice President Of Development
Technical Lead, Manufacturing Sciences & Technology
Executive Committee Member
Health Sciences Records & Archives Association
COO and Managing Partner
Dark Horse Consulting
CEO and Executive Chairman
Plasticell and Progenitor Labs
Clinical Account Manager
Group Lead, Midlands and Wales Advanced Therapy Treatment Program & head of Business and Project Development, Advanced Therapies
University of Birmingham
Executive Vice President Technical Operations
Chief Manufacturing Officer
Cell and Gene Thearpy Catapult
PhD Production Associate Director
VP - CMC
What did previous attendees have to say?
“Good mix of speakers”
“Impressed with the standard of presentations and openness of discussion”